Optinose Reports Third Quarter 2019 Financial Results and Recent Operational Highlights
12 nov. 2019 16h01 HE
|
Optinose, Inc.
XHANCE net revenue grew 30% to $8.7 million from second to third quarter 2019 XHANCE prescriptions increased 27% from second to third quarter 2019 Company expects XHANCE net revenues for...
Optinose to Report Third Quarter 2019 Financial Results and Corporate Updates on November 12, 2019
01 nov. 2019 08h00 HE
|
Optinose, Inc.
YARDLEY, Pa., Nov. 01, 2019 (GLOBE NEWSWIRE) -- Optinose (NASDAQ:OPTN), a pharmaceutical company focused on patients treated by ear, nose and throat (ENT) and allergy specialists, today announced...
Optinose Appoints Michael Richardson to New Position of Vice President, Business Development
04 oct. 2019 08h00 HE
|
Optinose, Inc.
YARDLEY, Pa., Oct. 04, 2019 (GLOBE NEWSWIRE) -- Optinose (NASDAQ:OPTN), a pharmaceutical company focused on patients treated by ear, nose and throat (ENT) and allergy specialists, today reported...
Optinose to Present at the 2019 Cantor Global Healthcare Conference
27 sept. 2019 08h00 HE
|
Optinose, Inc.
YARDLEY, Pa., Sept. 27, 2019 (GLOBE NEWSWIRE) -- Optinose (NASDAQ:OPTN), a pharmaceutical company focused on patients treated by ear, nose and throat (ENT) and allergy specialists, today announced...
OptiNose Announces License Agreement Related to ONZETRA XSAIL
26 sept. 2019 07h00 HE
|
Optinose, Inc.
YARDLEY, Pa., Sept. 26, 2019 (GLOBE NEWSWIRE) -- OptiNose, Inc. (Optinose) (NASDAQ:OPTN), a pharmaceutical company focused on patients treated by ear, nose and throat (ENT) and allergy specialists,...
Optinose Announces Departure of Chief Commercial Officer
17 sept. 2019 16h01 HE
|
Optinose, Inc.
YARDLEY, Pa., Sept. 17, 2019 (GLOBE NEWSWIRE) -- Optinose (NASDAQ:OPTN), a pharmaceutical company focused on patients treated by ear, nose and throat (ENT) and allergy specialists, today announced...
Optinose Announces $150 Million Debt Financing from Pharmakon
12 sept. 2019 16h05 HE
|
Optinose, Inc.
YARDLEY, Pa., Sept. 12, 2019 (GLOBE NEWSWIRE) -- Optinose (NASDAQ:OPTN), a pharmaceutical company focused on patients treated by ear, nose and throat (ENT) and allergy specialists, today reported...
Optinose Reports Second Quarter 2019 Financial Results and Recent Operational Highlights
12 août 2019 16h02 HE
|
Optinose, Inc.
XHANCE net revenue grew 68% to $6.7 million from first to second quarter 2019 XHANCE prescriptions increased 51% from first to second quarter 2019 Company expects XHANCE net revenues for 2019 to be...
Optinose to Report Second Quarter 2019 Financial Results and Corporate Updates on August 12, 2019
01 août 2019 16h30 HE
|
Optinose, Inc.
YARDLEY, Pa., Aug. 01, 2019 (GLOBE NEWSWIRE) -- Optinose (NASDAQ:OPTN), a pharmaceutical company focused on patients treated by ear, nose and throat (ENT) and allergy specialists, today announced...
Optinose to Present at the BMO Capital Markets Prescriptions for Success Healthcare Conference
20 juin 2019 08h00 HE
|
Optinose, Inc.
YARDLEY, Pa., June 20, 2019 (GLOBE NEWSWIRE) -- Optinose (NASDAQ:OPTN), a pharmaceutical company focused on patients treated by ear, nose and throat (ENT) and allergy specialists, today announced...